PG Stock Analysis: Procter & Gamble | NYSE
Household & Personal Products | NYSE, USA | Market Cap: 384.611m USD | 12M Return: 7.6% | US7427181091 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.45B
EPS Trend: 93.5%
Qual. Beats: 1
Rev. Trend: 87.9%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The Procter & Gamble Company (NYSE: PG) is a global manufacturer of branded consumer packaged goods, operating through five reportable segments: Beauty; Grooming; Health Care; Fabric & Home Care; and Baby, Feminine & Family Care. Its portfolio spans dozens of well-known brands across personal care, oral care, household cleaning, and hygiene categories, including Head & Shoulders, Pantene, Olay, Gillette, Oral-B, Vicks, Tide, Pampers, and Charmin. The company distributes its products through a wide range of retail channels, including mass merchandisers, grocery stores, drug stores, e-commerce platforms, and professional channels, as well as direct-to-consumer sales. P&G was founded in 1837 and is headquartered in Cincinnati, Ohio.
As a Mega Cap company in the Consumer Staples sector and Household Products sub-industry, P&Gs business model centers on building and defending market-leading brands in categories with relatively stable, recurring demand. Its scale, multi-category portfolio, and global distribution network support broad consumer reach and category diversification across both developed and emerging markets.
- Strong dollar pressures international revenue and earnings translation
- Commodity input costs and freight pressure gross margin outlook
- Gillette grooming faces competition from direct-to-consumer razor brands
| Net Income: 16.0b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA -0.19 > 1.0 |
| NWC/Revenue: -14.20% < 20% (prev -12.81%; Δ -1.40% < -1%) |
| CFO/TA 0.15 > 3% & CFO 19.9b > Net Income 16.0b |
| Net Debt (24.4b) to EBITDA (24.5b): 1.00 < 3 |
| Current Ratio: 0.72 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.41b) vs 12m ago -1.21% < -2% |
| Gross Margin: 49.78% > 18% (prev 50.98%; Δ -1.20% > 0.5%) |
| Asset Turnover: 67.44% > 50% (prev 66.56%; Δ 0.88% > 0%) |
| Interest Coverage Ratio: 15.84 > 6 (EBIT TTM 21.3b / Interest Expense TTM 1.34b) |
| A: -0.09 (Total Current Assets 32.5b - Total Current Liabilities 45.0b) / Total Assets 133b |
| B: 1.04 (Retained Earnings 138b / Total Assets 133b) |
| C: 0.16 (EBIT TTM 21.3b / Avg Total Assets 130b) |
| D: 0.71 (Book Value of Equity 55.1b / Total Liabilities 77.8b) |
| Altman-Z'' = 4.60 = AA |
| DSRI: 0.99 (Receivables 6.62b/6.49b, Revenue 87.9b/84.9b) |
| GMI: 1.02 (GM 50.98% / 49.78%) |
| AQI: 0.94 (AQ_t 0.56 / AQ_t-1 0.60) |
| SGI: 1.04 (Revenue 87.9b / 84.9b) |
| TATA: -0.03 (NI 16.0b - CFO 19.9b) / TA 133b) |
| Beneish M = -3.03 (Cap -4..+1) = AA |
As of October 29, 2026, the stock is trading at USD 158.26 with a total of 5,179,489 shares traded. Over the past week, the price has changed by +1.57%, over one month by +6.90%, over three months by +7.00% and over the past year by +7.59%.
Current recommended Stop Loss: 154.00 (which is 2.7% or 1.4 ATR below the current price).
Procter & Gamble has received a consensus analysts rating of 3.84. Therefore, it is recommended to buy PG.
- StrongBuy: 8
- Buy: 5
- Hold: 12
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 162.1 | 2.4% |
P/E Trailing = 23.6896
P/E Forward = 21.2314
P/S = 4.4192
P/B = 6.456
P/EG = 3.792
Revenue TTM = 87.9b USD
EBIT TTM = 21.3b USD
EBITDA TTM = 24.5b USD
Long Term Debt = 22.8b USD (from longTermDebt, last fiscal year)
Short Term Debt = 17.0b USD (from shortTermDebt, last quarter)
Debt = 39.8b USD (from shortLongTermDebtTotal, last quarter) + Leases 887.0m
Net Debt = 24.4b USD (calculated: Debt 39.8b - CCE 15.4b)
Enterprise Value = 409b USD (385b + Debt 39.8b - CCE 15.4b)
Interest Coverage Ratio = 15.84 (Ebit TTM 21.3b / Interest Expense TTM 1.34b)
EV/FCF = 26.67x (Enterprise Value 409b / FCF TTM 15.3b)
FCF Yield = 3.75% (FCF TTM 15.3b / Enterprise Value 409b)
FCF Margin = 17.45% (FCF TTM 15.3b / Revenue TTM 87.9b)
Net Margin = 18.23% (Net Income TTM 16.0b / Revenue TTM 87.9b)
Gross Margin = 49.78% ((Revenue TTM 87.9b - Cost of Revenue TTM 44.2b) / Revenue TTM)
Gross Margin QoQ = 49.83% (prev 48.50%)
Tobins Q-Ratio = 3.07 (Enterprise Value 409b / Total Assets 133b)
Interest Expense / Debt = 3.37% (Interest Expense 1.34b / Debt 39.8b)
Taxrate = 20.85% (4.25b / 20.4b)
NOPAT = 16.8b (EBIT 21.3b * (1 - 20.85%))
Current Ratio = 0.72 (Total Current Assets 32.5b / Total Current Liabilities 45.0b)
Debt / Equity = 0.72 (Debt 39.8b / totalStockholderEquity, last quarter 55.1b)
Debt / EBITDA = 1.00 (Net Debt 24.4b / EBITDA 24.5b)
Debt / FCF = 1.59 (Net Debt 24.4b / FCF TTM 15.3b)
Total Stockholder Equity = 54.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.29% (Net Income 16.0b / Total Assets 133b)
RoE = 29.55% (Net Income TTM 16.0b / Total Stockholder Equity 54.2b)
RoCE = 27.59% (EBIT 21.3b / Capital Employed (Equity 54.2b + L.T.Debt 22.8b))
RoIC = 16.71% (NOPAT 16.8b / Invested Capital 101b)
WACC = 5.04% (E(385b)/V(424b) * Re(5.29%) + D(39.8b)/V(424b) * Rd(3.37%) * (1-Tc(0.21)))
Discount Rate = 5.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.44 | Cagr: -1.18%
[DCF] Terminal Value 75.79% ; FCFF base≈15.2b ; Y1≈15.6b ; Y5≈17.2b
[DCF] Fair Price = 104.4 (EV 267b - Net Debt 24.4b = Equity 242b / Shares 2.32b; r=8.35% [WACC [floored]]; 5y FCF grow 2.66% → 2.50% )
EPS Correlation: 93.47 | EPS CAGR: 2.61% | SUE: 4.0 | # QB: 1
Revenue Correlation: 87.90 | Revenue CAGR: 1.62% | SUE: 1.35 | # QB: 1
EPS current Quarter (2026-12-31): EPS=1.88 | Chg30d=+0.02% | Revisions=+12% | Analysts=19
EPS next Quarter (2027-03-31): EPS=1.65 | Chg30d=-0.33% | Revisions=-10% | Analysts=19
EPS current Year (2027-06-30): EPS=6.98 | Chg30d=-0.05% | Revisions=+0% | GrowthEPS=+1.2% | GrowthRev=+2.1%
EPS next Year (2028-06-30): EPS=7.39 | Chg30d=-0.11% | Revisions=-12% | GrowthEPS=+5.9% | GrowthRev=+3.0%
[Analyst] Revisions Ratio: -4% (up=11, down=12)